MBWNT tumours, and infant MBSHH tumours with desmoplastic/nodular (DN) pathology, are associated with high survival rates (i.e. favourable-risk) and receive reduced-intensity therapies, while MYC-amplified MBGroup3 and TP53-mutated MBSHH carry the highest risk and gravest prognoses [14, 31]. The gene discussed is TP53; the disease is neoplasm.